Now Enrolling: Clinical Trial for Type 1 Diabetes. See If You Qualify.

News

See our press releases and media coverage to read the most up-to-date news about our work.
Please contact COURcomms@lifescicomms.com with all media inquiries.

August 1, 2022 | Press Release
COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model
February 28, 2022 | Press Release
COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer
January 10, 2022 | Press Release
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
November 18, 2021 | Press Release
CBRE Arranges Expansion Lease for Cour Pharmaceuticals
November 4, 2021 | Press Release
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
October 19, 2021 | Press Release
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
October 4, 2021 | Press Release
U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)
September 16, 2021 | Press Release
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
October 22, 2019 | Press Release
Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
January 10, 2018 | Press Release
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
Scroll to Top